Article Information
History
- July 29, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- Anna E. Mammel1,
- Ging-Yuek Robin Hsiung2,
- Ali Mousavi2,3,
- Kelsey Hallett1,
- Ian R. Mackenzie4,
- Veronica Hirsch-Reinshagen4,
- Don Biehl1,
- Pradip Gill1,
- Mary Encarnacion3 and
- Hans Frykman1,2,3,*
- 1Neurocode USA Inc, Bellingham, WA USA
- 2Division of Neurology, Department of Medicine, University of British Columbia, BC Canada
- 3BC Neuroimmunology Laboratory, Vancouver, BC Canada
- 4Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC Canada
- ↵*Corresponding Author: Hans Frykman, MD PhD, BC Neuroimmunology, Rm. S-157 2211 Wesbrook Mall, Vancouver, BC, Canada V6T 2B5, Phone: 604-822-7175, Email: hans.frykman{at}ubc.ca
Posted July 29, 2024.
Alzheimer’s disease clinical decision points for two plasma p-tau217 laboratory developed tests in neuropathology confirmed samples
